To thoroughly explore the effects of baseline on the survival of cancer patient treated with PD-1/PD-L1 inhibitors, further subgroup analysis for monotherapy and combination therapy were conducted separately and the results were shown in below part (summarized in Figures 2 and 3). Here, PDCD1 is linked to cancer.